COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF MITOCHONDRIAL DISEASES

• US 20120277286A1
• Filed: 05/01/2012
• Published: 11/01/2012
• Est. Priority Date: 10/30/2009
• Status: Abandoned Application

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Youle, Richard J., Narendra, Derek, Suen, Der-Fen
• Application Number:
  US13/460,852
• Publication Number:
  US 20120277286A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: G01N 2800/00 Detection or diagnosis of diseases
• CPC Class Codes: G01N 2800/04 Endocrine or metabolic disorders
• CPC Class Codes: G01N 2800/06 Gastro-intestinal diseases
• CPC Class Codes: G01N 2800/16 Ophthalmology
• CPC Class Codes: G01N 2800/164 Retinal disorders, e.g. retinopathy
• CPC Class Codes: G01N 2800/2835 Movement disorders, e.g. Parkinson, Huntington, Tourette
• CPC Class Codes: G01N 2800/2857 Seizure disorders; Epilepsy
• CPC Class Codes: G01N 2800/38 Pediatrics
• CPC Class Codes: G01N 2800/385 Congenital anomalies
• CPC Class Codes: G01N 33/5079 Mitochondria
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention features compositions and methods for the treatment or prevention of diseases associated with a mitochondrial defect.

Claims

1. A method of reducing the number of defective mitochondria in a cell, the method comprising

(a) identifying a cell as having an increased number of defective mitochondria;

(b) contacting the cell with an agent that increases Pink1 or Parkin expression or biological activity in the cell, thereby reducing the number of defective mitochondria in the cell.

3. The method of claim 1, wherein the cell is an ocular cell, neuron, muscle cell, or oocyte.

6. The method of claim 1, wherein the agent is an expression vector encoding a Pink1 or Parkin polynucleotide.

8. The method of claim 1, wherein the defective mitochondria has a dysfunction selected from the group consisting of a reduction in the activity of a mitochondrial enzyme, reduced electron transport chain (ETC) activity, diminished membrane potential, increased reactive oxygen species production, mitochondrial fragmentation, calcium dysregulation, and a mutation in mitochondrial DNA (mtDNA).

10. The method of claim 1, wherein the agent is an uncoupling agent, carbonylcyanide-3-chlorophenylhydrazone (CCCP), or dinitrophenol.

19. The method of claim 1 or 14, wherein the method increases autophagy of small defective mitochondria that lack membrane potential.

20. The method of claim 1 or 14, wherein the method increases biogenesis of new mitochondria.

2. (canceled)

4-5. -5. (canceled)

7. (canceled)

9. (canceled)

11-13. -13. (canceled)

14. A method of treating or preventing a mitochondrial disease in a subject, the method comprising identifying the subject as having an increased number of defective mitochondria and administering to the subject an effective amount of an agent that increases Pink1 or Parkin expression or biological activity in a cell, thereby treating the disease.

15. The method of claim 14, wherein the agent is a mammalian expression vector encoding a Parkin or PINK1 polypeptide or fragment thereof.

16. The method of claim 14, wherein the disease is associated with a mitochondrial dysfunction selected from the group consisting of a reduction in the activity of a mitochondrial enzyme, reduced electron transport chain (ETC) activity, diminished membrane potential, increased reactive oxygen species production, mitochondrial fragmentation, calcium dysregulation, and a mutation in mitochondrial DNA (mtDNA).

17. The method of claim 14, wherein the disease is cancer;

diabetes mellitus;

a hereditary mitochondrial disease selected from the group consisting of Neurogenic muscular weakness-Ataxia-Retinitis pigmentosa (NARP), Multiple Sclerosis-like Syndrome (MSS);

Maternally Inherited CardioMyopathy (MCIM);

Progressive External Ophthalmoplegia (PEO);

Myoclonic Epilepsy with Ragged-Red Fibers (MERRF);

Myoneurogastrointestinal disorder and encephalopathy (MNGIE), Pearson Marrow syndrome, Kearns-Sayre-CPEO, Leber hereditary optic neuropathy (LHON), Aminoglycoside-associated deafness, Diabetes with deafness, Luft disease, Leigh syndrome (Complex I, COX, PDH), Alpers Disease, MCAD, SCAD, SCHAD, VLCAD, LCHAD, Glutaric aciduria II, and Lethal infantile cardiomyopathy;

or a mitochondrial disease that is not Parkinson'"'"'s disease.

55. A pharmaceutical composition formulated for use in the method of claim 14, the composition comprising an effective amount of Parkin or Pink1 in a pharmaceutically acceptable excipient.

56. A kit for treating a mitochondrial disease comprising the pharmaceutical composition of claim 55, wherein the kit further comprises instructions for identifying a subject in need of such treatment and directions for administering the pharmaceutical composition to a subject.

18. (canceled)

21-35. -35. (canceled)

36. A method for identifying a compound useful for the treatment of a mitochondrial disease, the method comprising:

(a) contacting a cell with a compound and an agent that disrupts mitochondrial function; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of a mitochondrial disease;

or

a method for identifying a compound useful for the treatment of a subject having a mitochondrial disease, the method comprising;

(a) contacting a cell derived from the subject with a compound and an agent that disrupts mitochondrial function; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of the subject having mitochondrial disease;

or

a method for identifying a compound useful for the treatment of a mitochondrial disease, the method comprising;

(a) contacting a cell with a compound and an agent that disrupts mitochondrial function; and

(b) identifying an increase of PINK1 or Parkin associated with mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that increases PINK1 or Parkin association with mitochondria in the cell is identified as useful for the treatment of a mitochondrial disease;

or

a method for identifying a compound useful for the treatment of a mitochondrial disease, the method comprising;

(a) contacting a cell comprising a mutation in mitochondrial DNA with a compound; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of a mitochondrial disease;

or

a method for identifying a compound useful for the treatment of a mitochondrial disease, the method comprising;

(a) contacting a cell with a compound; and

(b) identifying an increase of PINK1 or Parkin associated with mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that increases PINK1 or Parkin association with mitochondria in the cell is identified as useful for the treatment of a mitochondrial disease;

or

a method for identifying a compound useful for the treatment of a subject having a mitochondrial disease, the method comprising;

(a) contacting a cell derived from the subject with a compound; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of said mitochondrial disease in the subject;

or

a method for identifying a compound useful for the treatment of Parkinson'"'"'s disease, the method comprising;

(a) contacting a dopaminergic cell with a candidate compound and an agent that disrupts mitochondrial function; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of a Parkinson'"'"'s disease;

or

a method for identifying a compound useful for the treatment of Parkinson'"'"'s disease, the method comprising;

(a) contacting a cell comprising a mutation in Pink1 or Parkin with a candidate compound; and

(b) identifying a reduction in the number of defective mitochondria in the cell relative to a control cell not contacted with the candidate compound, wherein a compound that reduces the number of defective mitochondria in the cell is identified as useful for the treatment of a Parkinson'"'"'s disease.

46. The method of claim 36, wherein the compound is a polypeptide, polynucleotide, small chemical compound, or microRNA.

37-45. -45. (canceled)

47-50. -50. (canceled)

51. A method for ameliorating Parkinson'"'"'s disease in a subject, the method comprising administering to the subject an agent that reduces the biological activity or expression of PARL.

52. The method of claim 51, wherein the agent is i) an inhibitory nucleic acid molecule that reduces the expression of PARL polynucleotide or polypeptide;

or ii) a protease inhibitor that reduces PARL proteolytic activity.

53. The method of claim 52, wherein the inhibitory nucleic acid molecule is an siRNA, shRNA, or antisense polynucleotide.

54. (canceled)